ORs (95% CIs) of mortality post haemorrhagic stroke based on prior therapy
| Mortality | Unadjusted | Model A | Model B | Model C |
| 0–7 days, N | 451 | 451 | 414 | 333 |
| No therapy† | 1.00 | 1.00 | 1.00 | 1.00 |
| Aspirin | 0.99 (0.60 to 1.62) | 1.03 (0.62 to 1.71) | 1.24 (0.73 to 2.12) | 1.31 (0.64 to 2.68) |
| Warfarin | 2.06 (1.13 to 3.79)** | 2.13 (1.15 to 3.96)** | 2.02 (1.04 to 3.89)** | 2.91 (1.23 to 6.89)** |
| 0–30 days, N | 451 | 451 | 414 | 378 |
| No therapy† | 1.00 | 1.00 | 1.00 | 1.00 |
| Aspirin | 1.62 (1.05 to 2.50)** | 1.46 (0.93 to 2.29) | 1.70 (1.05 to 2.74)** | 2.36 (1.18 to 4.71)** |
| Warfarin | 1.83 (1.02 to 3.28)** | 1.76 (0.97 to 3.21) | 1.79 (0.95 to 3.38) | 2.37 (1.00 to 5.61)** |
| 0–60 days, N | 451 | 451 | 417 | 380 |
| No therapy† | 1.00 | 1.00 | 1.00 | 1.00 |
| Aspirin | 1.62 (1.06 to 2.48)** | 1.40 (0.90 to 2.19) | 1.63 (1.02 to 2.61)** | 2.18 (1.10 to 4.29)** |
| Warfarin | 2.02 (1.13 to 3.61)** | 1.90 (1.04 to 3.46)** | 2.07 (1.10 to 3.89)** | 2.86 (1.20 to 6.84)** |
| 0–90 days, N | 451 | 451 | 417 | 380 |
| No therapy† | 1.00 | 1.00 | 1.00 | 1.00 |
| Aspirin | 1.80 (1.18 to 2.75)* | 1.54 (0.99 to 2.40) | 1.83 (1.14 to 2.93)** | 2.56 (1.27 to 5.13)* |
| Warfarin | 1.99 (1.11 to 3.55)** | 1.85 (1.02 to 3.37)** | 2.02 (1.08 to 3.81)** | 2.82 (1.16 to 6.86)** |
| 0–365 days, N | 451 | 451 | 417 | 380 |
| No therapy† | 1.00 | 1.00 | 1.00 | 1.00 |
| Aspirin | 1.71 (1.12 to 2.61)** | 1.36 (0.86 to 2.13) | 1.57 (0.98 to 2.54) | 1.67 (0.89 to 3.12) |
| Warfarin | 1.87 (1.04 to 3.34)** | 1.67 (0.91 to 3.08) | 1.89 (1.00 to 3.59) | 2.44 (1.06 to 5.62)** |
Model A: adjusted for age, age squared and gender.
Model B: adjusted for age, age squared, gender and premorbid Rankin score.
Model C: adjusted for age, age squared, gender, premorbid Rankin score and Oxfordshire Community Stroke Project (OCSP) stroke type.
*p<0.05, **p<0.01.
↵† Reference category.